FindTrial
Sign In

Expanded Access to Burosumab

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03775187
Enrollment
Unknown
Registered
2018-12-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumor-Induced Osteomalacia, X-linked Hypophosphatemia

Keywords

Expanded Access, Compassionate Use, XLH, TIO

Brief summary

Individual patient expanded access requests may be considered for patients who have no other treatment options

Detailed description

Expanded access may be available outside of the US in countries prior to approval by the local regulatory agencies. For full details, please visit the links provided below.

Interventions

BIOLOGICALBurosumab

Sponsors

Kyowa Kirin Co., Ltd.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL

Inclusion criteria

\-

Exclusion criteria

\-

Contacts

Primary ContactDevelopment Division Project Management Department
kkd.clintrial.82@kyowakirin.com609-919-1100

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026